Kammei Rai 研究室

主宰者：Kammei Rai

岡山大学・Okayama University Hospital

AI 要約（直近 5 年の研究成果）

本研究室は、肺癌の治療抵抗性の解明と克服を主要なテーマとしています。特に、遺伝子変異を持つ肺癌（EGFR変異やALK融合遺伝子を有する非小細胞肺癌）に対して、分子標的薬が効かなくなる仕組みを明らかにし、より有効な治療法の開発に取り組んでいます。マウスモデルを用いた動物実験と培養細胞での検証を組み合わせることで、耐性メカニズムを詳細に調べています。研究の主たる知見は、標的薬の投与により一時的には腫瘍が縮小するものの、腫瘍内の免疫環境が十分に活性化されず、がん細胞の一部が生き残って耐性を獲得することにあります。この問題に対して、複数の免疫調節薬（免疫チェックポイント阻害薬、STING作動薬、抗TGF-β薬など）を併用することで、免疫細胞の活動を高める戦略を検討しています。また、獲得耐性のメカニズムの同定や、耐性が生じた後の代替薬剤の有効性についても研究を進めており、最終的には治癒困難な肺癌患者の予後改善を目指しています。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（29 件）

[2026] PP01.59: ABBIL1TY NSCLC-06: A Global, Randomized, Open-Label, Phase 3 Trial of Acasunlimab in Combination with Pembrolizumab vs Docetaxel in Checkpoint Inhibitor–Experienced Patients with PD-L1+ Metastatic Non-Small Cell Lung Cancer
DOI: https://doi.org/10.1016/j.jtho.2026.103802
[2026] <scp>TGF</scp> ‐β Inhibitor Potentiates Osimertinib‐Induced Anti‐Tumor Immunity in Egfr ‐Mutant Lung Cancer
DOI: https://doi.org/10.1111/cas.70352
[2026] Automatic Detection of Turning Over in Bed with Protection of Privacy Using Four Low-resolution Thermal Sensors to Support Nursing Care
DOI: https://doi.org/10.14326/abe.15.265
[2026] Afatinib Overcomes Osimertinib Resistance via Egfr <scp>V804F</scp> Mutation in a Syngeneic Egfr ‐Mutant Lung Cancer Mouse Model
DOI: https://doi.org/10.1111/cas.70431
[2026] Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment
DOI: https://doi.org/10.3390/curroncol33060315
[2026] Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr ‐mutated lung cancer
DOI: https://doi.org/10.1002/1878-0261.70264
[2025] Supplementary Figure S3 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.30516018
[2025] Supplementary Figure S4 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.30516015
[2025] Data from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.c.8125941
[2025] Supplementary Figure S1 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.30516024

続きを表示（残り 19 件）

[2025] Supplementary Figure S2 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.30516021
[2025] Endotracheal and Endobronchial Metastases in Epidermal Growth Factor Receptor Exon 19 Deletion Lung Adenocarcinoma: A Case Successfully Managed with Bronchoscopic Therapy and Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
DOI: https://doi.org/10.2169/internalmedicine.6220-25
[2025] Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.mct-25-0002
[2025] A Prompt Diagnosis of Ascites and Dramatic Effect of Alectinib for Advanced Lung Adenocarcinoma Harboring EML4-ALK Fusion
DOI: https://doi.org/10.2169/internalmedicine.5397-25
[2025] Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines
DOI: https://doi.org/10.1016/j.lungcan.2025.108415
[2025] Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
DOI: https://doi.org/10.1038/s41598-025-87232-z
[2024] Concomitant osimertinib and <scp>antituberculosis</scp> therapy in an elderly patient with <scp>EGFR‐mutated</scp> lung cancer and pulmonary tuberculosis: A case report
DOI: https://doi.org/10.1111/1759-7714.15324
[2024] A Prompt Diagnosis and Treatment of a Case of Nuclear Protein of the Testis Carcinoma Characterized by a Bronchial Lesion and High Serum Alpha-fetoprotein Level Following Genomic Testing
DOI: https://doi.org/10.2169/internalmedicine.2938-23
[2024] Single-lung Transplant in a Patient with Mycobacterium avium Pulmonary Disease Successfully Treated with Amikacin Liposome Inhalation Suspension
DOI: https://doi.org/10.2169/internalmedicine.3854-24
[2024] Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy
DOI: https://doi.org/10.1016/j.rmcr.2024.102104
[2023] Respiratory disease in workers handling cross-linked water-soluble acrylic acid polymer
DOI: https://doi.org/10.1371/journal.pone.0284837
[2021] Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease
DOI: https://doi.org/10.2169/internalmedicine.6470-20
[2021] A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R
DOI: https://doi.org/10.1093/jjco/hyab048
[2021] SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1- , or EGFR -altered Non–small Cell Lung Cancer
DOI: https://doi.org/10.1158/1535-7163.mct-20-0965
[2021] Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients
DOI: https://doi.org/10.1016/j.resinv.2020.12.001
[2021] VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers
DOI: https://doi.org/10.1111/cas.14801
[2021] Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR‑mutant lung cancer with HIF‑1α/TGF‑α expression
DOI: https://doi.org/10.3892/ol.2021.12900
[2021] Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan
DOI: https://doi.org/10.2169/internalmedicine.7124-21
[2021] Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.
DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.e20590

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（29 件）

科研費（0 件）

所属学会・役職（0 件）